The significance of the list is that Amferia, as one among the 33 young Swedish companies is deemed to have high potential to become future growth companies. The companies selected to be on the list after rigorous evaluation by the jury, are judged to be innovative, have scalable business models and have the potential to grow quickly on the Swedish and global market.
Infections are a difficult healthcare problem, exacerbated by antibiotic resistance. Amferia’s innovative antimicrobial material is an effective, safe and sustainable way to address life threatening bacterial infections, especially within the filed of medical devices. This is equally important in both human and animal health, and we are bringing products built on our technology rapidly to the market.
The recognition by Nyteknik is an important achievement for Amferia attesting to our measured yet rapid progress of a deep technology breakthrough innovation to the clinic. And most importantly, our deepest gratitude to our collaborators in the clinics who clearly saw the need and importance of our technology in addressing an acute global healthcare threat.
